Ray, a 62-year-old retired mail carrier from Memphis, had lived with type 2 diabetes for eleven years. He managed it reasonably well: A1c mostly in the low sevens, blood pressure controlled, no amputations, no serious eye complications. He credited his nephrologist, Dr. Simmons, with keeping him honest.
What Dr. Simmons tracked closely was Ray’s eGFR, the estimated glomerular filtration rate that measures how well the kidneys are filtering waste from the blood. At diagnosis, Ray’s eGFR was 71. By 2021 it had declined to 44. By 2023 it was 38. The trajectory was not catastrophic, but it was going in one direction.
“She said dialysis wasn’t inevitable,” Ray recalled, “but the math wasn’t working in my favor.”
Then Dr. Simmons told him about a trial that had been stopped early. Not because of harm. Because semaglutide had performed well enough that continuing to give the control group a placebo was considered unethical.
Why Kidney Disease in Diabetes Is So Common and So Serious
Diabetic kidney disease, now more precisely called diabetic nephropathy or chronic kidney disease in the setting of type 2 diabetes (CKD-T2D), is the leading cause of kidney failure in the United States. Approximately 40 percent of people with type 2 diabetes will develop some degree of CKD over their lifetime¹.
The mechanism is well established: chronic hyperglycemia damages the glomerular capillaries, the tiny filtration units inside each kidney. Elevated blood pressure compounds the damage by increasing the mechanical stress on those same structures. Protein begins leaking into the urine, a finding called albuminuria, which is both a marker of kidney injury and a driver of further damage.
Once eGFR falls below 60, patients are classified as having CKD stage 3. Below 30 is stage 4. Below 15 is kidney failure, requiring dialysis or transplant. For patients with CKD-T2D, the standard-of-care additions over the past decade have included angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACE/ARB) and, more recently, SGLT2 inhibitors such as empagliflozin and dapagliflozin, which demonstrated kidney-protective benefits in their own outcome trials.
Semaglutide was not expected to be next. It turned out it was.
The FLOW Trial: Design and Population
The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) enrolled 3,533 adults with type 2 diabetes and chronic kidney disease at more than 380 sites across 28 countries. To be eligible, participants needed an eGFR between 24 and 54 mL/min/1.73m² and a urine albumin-to-creatinine ratio of at least 300 mg/g, confirming moderate-to-severe albuminuria. This was a high-risk population: patients already showing significant kidney dysfunction and protein leakage.
Participants were randomized to semaglutide 1.0 mg weekly (the standard GLP-1 diabetes dose, not the higher 2.4 mg obesity dose) or placebo. Standard-of-care treatment continued in both arms, including ACE/ARB use and SGLT2 inhibitors if already prescribed.
The primary composite outcome was: kidney failure (dialysis, transplant, or eGFR below 15), a sustained decline of at least 50% in eGFR, death from kidney disease, or death from cardiovascular causes².
The Data Safety Monitoring Board Stopped the Trial Early
In late 2023, the DSMB reviewing FLOW trial data crossed a pre-specified efficacy boundary. The results were clear enough that continuing to administer placebo to the control group was no longer considered ethically justifiable. The trial was stopped.
Results were published in the New England Journal of Medicine in May 2024:
| Outcome | Semaglutide | Placebo | Hazard Ratio |
| Primary composite endpoint | 11.4% | 14.9% | 0.76 (95% CI 0.66-0.88) |
| Kidney failure specifically | 5.5% | 7.2% | 0.77 (95% CI 0.62-0.96) |
| Cardiovascular death, MI, or stroke | 12.3% | 14.4% | 0.82 (95% CI 0.70-0.96) |
| All-cause mortality | 9.4% | 11.1% | 0.80 (95% CI 0.67-0.95) |
Semaglutide reduced the risk of the primary kidney endpoint by 24%, reduced cardiovascular events by 18%, and reduced all-cause mortality by 20%. These benefits occurred on top of standard care, including ACE/ARB therapy and SGLT2 inhibitor use in a significant portion of the trial population.
The magnitude of kidney protection was consistent across eGFR subgroups, with meaningful benefit seen even in participants who started the trial with eGFR below 45.
Why GLP-1 Might Protect the Kidneys
Several mechanisms have been proposed, and the evidence increasingly suggests they operate in parallel.
Hemodynamic effects. GLP-1 receptor activation reduces intraglomerular pressure by dilating afferent arterioles and modulating renal blood flow. This reduces the mechanical stress that accelerates glomerular damage. The effect is distinct from but potentially complementary to the hemodynamic mechanism of SGLT2 inhibitors, which act primarily on tubuloglomerular feedback³.
Inflammation reduction. Chronic low-grade inflammation drives kidney disease progression in diabetes. GLP-1 receptor agonism suppresses NF-kB signaling, reduces circulating inflammatory cytokines, and appears to directly modulate the activity of mesangial cells and podocytes, the specialized kidney cells most vulnerable to diabetic injury.
Albuminuria reduction. FLOW participants on semaglutide showed meaningful reductions in urine albumin-to-creatinine ratio compared to placebo. Albuminuria is not just a marker; it drives further glomerular injury through activation of complement and inflammatory pathways. Reducing protein leakage slows a feedforward loop of kidney damage⁴.
Metabolic improvement. Improved glycemia and reduced visceral adiposity reduce the systemic metabolic stress that drives diabetic nephropathy. Weight loss alone, however, doesn’t explain the full magnitude of FLOW’s kidney benefit, as the same hemodynamic and anti-inflammatory effects likely contribute independently.
Where Semaglutide Fits in CKD Treatment Now
The FLOW trial was designed against a background of existing standard care. A large proportion of FLOW participants were already on SGLT2 inhibitors, which have their own established kidney-protective trial data. The fact that semaglutide showed additive benefit on top of SGLT2 inhibitors is clinically significant.
This is now the picture emerging for patients with CKD and type 2 diabetes:
ACE inhibitor or ARB: Reduces proteinuria and slows progression. Standard of care for decades.
SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin): Demonstrated kidney protection in their own outcome trials. Now widely recommended for CKD-T2D.
GLP-1 receptor agonist (semaglutide): Now with FLOW’s data showing additive kidney and cardiovascular benefit on top of SGLT2 inhibitor use.
The realistic clinical picture for a patient like Ray is a regimen that combines all three classes if tolerated. No single agent gets full credit for kidney protection in 2024; combination therapy targeting multiple mechanisms has become the goal.
The FDA is reviewing semaglutide’s FLOW data for a potential CKD-T2D indication. An approval would add a kidney protection label to semaglutide’s existing diabetes and cardiovascular indications.
What This Means If Your Kidney Numbers Are Moving
For patients with type 2 diabetes, eGFR and UACR are among the most important numbers in their lab panel. Many are never told this directly.
An eGFR below 60 means your kidneys are filtering at less than 60 percent of normal capacity. A UACR above 30 mg/g means protein is leaking into your urine, an early damage signal. A UACR above 300 mg/g, the level required for FLOW enrollment, represents significant proteinuria and meaningfully elevated progression risk.
If you have type 2 diabetes and your kidney numbers are moving in the wrong direction, and you are not already on a GLP-1 medication, the FLOW data is a reason to raise that conversation with your nephrologist or endocrinologist. If you are already on semaglutide for glucose management, the FLOW trial suggests you may be receiving kidney protection as a concurrent benefit worth tracking.
GLP-1 medications do require dose adjustment considerations in CKD. At eGFR below 15, use requires specialist guidance. Most patients in the mild-to-moderate CKD range can use semaglutide, but dosing decisions and monitoring should involve a nephrologist.
Key Takeaway
The FLOW trial enrolled 3,533 adults with type 2 diabetes and chronic kidney disease, and was stopped early by the data safety monitoring board because semaglutide 1.0 mg demonstrated a 24% relative risk reduction in the primary kidney composite endpoint (kidney failure, 50% eGFR decline, renal or cardiovascular death). Secondary results showed 18% fewer cardiovascular events and 20% lower all-cause mortality. These benefits occurred on top of standard care including SGLT2 inhibitor use in many participants. The mechanism likely involves hemodynamic, anti-inflammatory, and antiproteinuric effects that operate alongside, and appear additive to, existing kidney-protective therapies. For patients with type 2 diabetes and declining kidney function, the FLOW data represents a significant change in treatment options.
Category
GLP-1, Semaglutide, Kidney Disease, Chronic Kidney Disease, CKD, FLOW Trial, Diabetic Nephropathy, eGFR, Albuminuria, Type 2 Diabetes, SGLT2 Inhibitors, Metabolic Health
References
¹ American Diabetes Association. Standards of Medical Care in Diabetes. Section: Chronic Kidney Disease and Risk Management. Diabetes Care. 2024.
² Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391:109-121.
³ GLP-1 receptor activation and renal hemodynamics: afferent arteriolar dilation, intraglomerular pressure reduction, and tubuloglomerular interaction. Journal of the American Society of Nephrology. 2023.
⁴ Albuminuria reduction with GLP-1 receptor agonists: clinical data and proposed mechanisms including podocyte protection and mesangial cell modulation. Kidney International. 2024.
⁵ SGLT2 inhibitor kidney outcome trials: CREDENCE, DAPA-CKD, EMPA-KIDNEY. Combined evidence for CKD in type 2 diabetes. NEJM. 2019-2023.
Disclaimer
This article is for educational purposes only and is not medical advice. Chronic kidney disease requires evaluation and management by a qualified nephrologist or endocrinologist. Semaglutide does not currently carry an FDA-approved CKD-specific indication; FLOW data is under regulatory review. Dosing of GLP-1 medications in patients with reduced kidney function requires specialist guidance. Do not start, stop, or modify any kidney disease treatment without consulting your prescribing physician. eGFR and UACR results should be interpreted in the context of your full clinical picture by your healthcare provider.
